Company intelligence / Profile preview

Resurge Therapeutics

San Jose, California, United Statesresurgetherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Resurge Therapeutics is developing a minimally invasive implantable drug delivery system targeting the prostate gland to treat lower urinary tract symptoms caused by benign prostatic hyperplasia. Their lead candidate, RT-310, is in Phase 1 clinical trials in Australia and New Zealand as of April 2024. The company aims to provide effective local therapy while minimizing systemic side effects and improving patient compliance compared to oral or systemic medications.

Therapeutic areas: Men's Health
Modalities: Small moleculesLocal drug delivery implants
Industry: Biotech

Drug pipeline

1 asset

RT-310

Unknown

Beyond the preview

Go deeper on Resurge Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resurge Therapeutics.

Explore the full profile